In summary, the identification of a mosaic activating FGFR2 variant in an individual with a specific neurocutaneous phenotype and the initial clinical diagnosis of SFM syndrome highlights a tremendous overlap of the genotypic and phenotypic spectrum of mosaic RASopathies and FGFR-associated syndromes. Here, FGFR2 is linked to RASopathy.